Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational, Retrospective, Postmarketing Safety Study of Trivalent Cell Culture Seasonal Influenza Vaccination (TIVc) (Optaflu) among Adults in Routine UK Care

Next Previous
X
Search
Trial Profile

An Observational, Retrospective, Postmarketing Safety Study of Trivalent Cell Culture Seasonal Influenza Vaccination (TIVc) (Optaflu) among Adults in Routine UK Care

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza vaccine (Optaflu) (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions

    • Most Recent Events

    • 29 Nov 2017 New trial record
    • 20 Nov 2017 According to results published in the Pharmacoepidemiology and Drug Safety Journal, this study was stopped when just over half of the planned number of exposures had been identified because the product marketing was discontinued.
    • 20 Nov 2017 Results published in the Pharmacoepidemiology and Drug Safety Journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top